Deliver Agents

Deliver Agents AffiNANOTECH" encompasses the application of affinity-functionalized nanotechnology platforms for the precise delivery of therapeutic or diagnostic agents. This strategy integrates nanoparticles engineered with specific affinity ligands to target and transport a variety of payloads—including drugs, nucleic acids, proteins, and imaging agents—directly to designated cells or tissues. 

Technical Content and Mechanism

  • Nanoparticle Platform Design:
    • Material Selection: Depending on the delivery agent’s nature and the target application, nanoparticles may be constructed from biodegradable polymers (PLGA, chitosan), lipids (liposomes), dendrimers, or inorganic materials (gold, silica).
  • Affinity Functionalization:
    • Ligand Conjugation: Affinity ligands such as antibodies, peptides, aptamers, or small molecules are covalently attached to the nanoparticle surface using chemistries like EDC/NHS coupling, click reactions, or thiol–maleimide conjugation.
  • Targeting and Cellular Uptake:
    • Specific Binding: Affinity ligands guide nanoparticles to target cells by binding specific surface receptors, concentrating delivery at the desired site.

Applications

  • Targeted Chemotherapy:
    AffiNANOTECH platforms can deliver chemotherapeutic drugs directly to cancer cells by targeting tumor-associated antigens, reducing systemic toxicity and improving drug accumulation at the tumor site.
  • Gene Delivery:
    Nanoparticles functionalized with affinity ligands can transport genetic material (DNA, RNA) to specific cells for gene therapy applications, enhancing transfection efficiency and specificity while minimizing immune responses.
  • Protein and Enzyme Replacement Therapy:
    Delivering functional proteins or enzymes to cells that are deficient can be achieved using affinity-targeted nanoparticles, protecting these fragile biomolecules and ensuring they reach the intracellular location where needed.

Deliver Agents AffiNANOTECH combines sophisticated nanoparticle engineering with affinity-based targeting to create highly specific delivery vehicles for a broad range of agents. By optimizing nanoparticle composition, affinity ligand attachment, and controlled release mechanisms, this approach enhances targeting precision, improves therapeutic outcomes, and reduces off-target effects across various biomedical applications.

AffiNANOTECH® 16:0 TAP
CAT# AFG-MCX-1365
Size: 100 mg
0.00 0.0 USD
AffiNANOTECH® LNP Lipid-2
CAT# AFG-MCX-1364
Size: 100 mg
0.00 0.0 USD
AffiNANOTECH® DMPE
CAT# AFG-MCX-1363
Size: 100 mg
0.00 0.0 USD
AffiNANOTECH® 18:1 Ethylene Glycol
CAT# AFG-MCX-1362
Size: 100 mg
0.00 0.0 USD
AffiNANOTECH® Dielaidoylphosphatidylethanolamine
CAT# AFG-MCX-1361
Size: 100 mg
0.00 0.0 USD